Radiopharm Theranostics Limited (AU:RAD) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Radiopharm Theranostics Limited has announced the launch of its Level 1 American Depositary Receipt (ADR) program, allowing shareholders to trade shares in the U.S. without cross-border complications. The program is seen as a precursor to the company’s plan to list on Nasdaq, aiming to attract U.S. institutional and retail investors with trade initially taking place over-the-counter. The ADR initiative aligns with Radiopharm’s strategic efforts to broaden its investor base in anticipation of its proposed Nasdaq listing.
For further insights into AU:RAD stock, check out TipRanks’ Stock Analysis page.